Clinical Trial Details


Research Study Summary

Enlarged Prostate (BPH) Study


A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Intraprostatic Administration of BOTOX 200 U (Botulinum Toxin Type A) Purified Neurotoxin Complex to Treat Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia

Patient Inclusion Criteria:

  • Males 45 years or older weighing at least 110 pounds
  • Lower urinary tract symptoms for at least the last 6 months, currently taking or history of taking approved prostate medications

Patient Exclusion Criteria:

  • Prostatitis, prostate cancer, bladder cancer, previous prostate surgery or bladder surgery
  • Frequent UTI's, symptomatic kidney stones or planned intervention for kidney stones
  • Uninvestigated hematuria, Interstitial Cystitis, neurological disorders
  • Clotting factor deficiencies or platelet disorders, HIV, uncontrolled diabetes
  • Over-active bladder or bladder medications, urinary incontinence or retention, catheter usage

To Learn more

CW ID: 178206
Date Last Changed: July 19, 2013

Clinical Trial Snapshot

45 and up
Overall Status
Facility Type


West Coast Clinical Research
5525 Etiwanda Ave.
Suite 202
Tarzana, CA 91356
Phone: 818-776-0820
Fax: 818-776-1269

View Map

Research Center Information:

West Coast Clinical Research

Volunteer for this Trial

If you would like to learn more about participating in this research study, please email the trial contact using the form below. We value your privacy and your information will only be used by the research center to contact you regarding this study.

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.